All In Biotech

Drug Trial Radar · NCT03767075

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Dec 10, 2018

Primary completion

May 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Vall d'Hebron Institute of OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Roche Pharma AG; IQVIA Pty Ltd; Taisho Pharmaceutical Co., Ltd.; Janssen, LP
First posted
Dec 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The global objective of this Basket of Basket study is to evaluate the antitumor activity of each matched therapies that will be evaluated through the study in small molecularly selected populations. The objective of module 1 wil be to determine the overall response rate (ORR) at 12 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of atezolizumab in each of the arms of the module. All patients in genomically selected populations will receive atezolizumab 1200 mg IV every 3 weeks. The objective of module 2 wil be to determine the overall response rate (ORR) at 16 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of futibatinib in each of the arms of the module. All patients in genomically selected populations will receive will receive futibatinib, 20 mg, once daily (QD) in 28-day cycles. The objective of module 3 wil be to determine the overall response rate (ORR) at 12 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of amivantamab in each of the arms of the module. All patients in genomically selected populations will receive amivantamab 1050 mg intravenously (IV) for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles).

Conditions

  • Advanced Solid Tumor

Interventions

  • AtezolizumabDrug

    1200 mg, administered IV, once every 3 weeks

  • FutibatinibDrug

    20 mg administered orally, once daily (QD) continuously in 28-day cycles.

  • AmivantamabDrug

    1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rateTime frame: From the first dose date of study treatment to first CR or PR, whichever came earlier, up to 12 weeks (Module 1 & 3) and 16 weeks (Module 2)

Locations

8 sites in 7 countries. Site status is shown where the registry gives one.

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Universitätsklinikum Dresden

    Dresden, Germany · Recruiting

  • Deutsches Krebsforschungszentrum (NCT/DKFZ)

    Heidelberg, Baden-Wurttemberg, Germany · Recruiting

  • Instituto Nazionale dei Tumori di Milano

    Milan, Italy · Recruiting

  • Nederland Kanker Instituut (NKI)

    Amsterdam, Netherlands · Recruiting

  • Hospital Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Karolinska University Hospital Solna

    Stockholm, Sweden · Recruiting

  • Cancer Research UK Cambridge Centre

    Cambridge, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.